Get started
Author

Lucie Lépine

Observed name: Lucie Lepine
Institution: Sanofi (France)
Observed institution: Sanofi (France)
OpenAlex ID: A5109526344
Advanced chronic kidney disease populations have elevated trimethylamine N-oxide levels associated with increased cardiovascular events
2016 · Richard B. Kim, Bridget L. Morse, et al. · Kidney International · 179
Targeting CD38 and PD-1 with isatuximab plus cemiplimab in patients with advanced solid malignancies: results from a phase I/II open-label, multicenter study
2022 · Paolo Andrea Zucali, Chia-Chi Lin, et al. · Journal for ImmunoTherapy of Cancer · 43
PDF
Isatuximab Monotherapy for Desensitization in Highly Sensitized Patients Awaiting Kidney Transplant
2023 · Flavio Vincenti, Oriol Bestard, et al. · Journal of the American Society of Nephrology · 42
Isatuximab in combination with cemiplimab in patients with relapsed/refractory multiple myeloma: A phase 1/2 study
2023 · Alexander Lesokhin, Richard LeBlanc, et al. · Cancer Medicine · 14
PDF
Isatuximab in Combination with Lenalidomide and Dexamethasone in Patients with High-Risk Smoldering Multiple Myeloma: Updated Safety Run-in Results from the Randomized Phase 3 Ithaca Study
2022 · Maria-Victoria Mateos, Paula Rodriguez Otero, et al. · Blood · 11
A phase 1/2, open‐label, multicenter study of isatuximab in combination with cemiplimab in patients with lymphoma
2022 · Carmelo Carlo‐Stella, Pier Luigi Zinzani, et al. · Hematological Oncology · 9
P-137: ITHACA, a randomized multicenter phase 3 study of Isatuximab in combination with Lenalidomide and Dexamethasone in high-risk smoldering Multiple Myeloma: safety run-in preliminary results
2021 · Irene Ghobrial, Paula Rodríguez-Otero, et al. · Clinical Lymphoma Myeloma & Leukemia · 7
Phase 1/2, open-label, first-in-human study of the anti-GPC3 T-cell engager SAR444200 in patients with advanced solid tumors: Updated efficacy and biomarker analysis.
2025 · Ecaterina Elena Dumbrava, Anthony El-Khoueiry, et al. · Journal of Clinical Oncology · 1
PDF
A Phase 1/2, Open-Label, Multicenter Study of Isatuximab in Combination with Cemiplimab in Patients with Lymphoma
2021 · Carmelo Carlo-Stella, Pier Luigi Luigi Zinzani, et al. · Blood · 1
Pharmacokinetics and biomarker analysis from a phase 1/2 open-label study of the anti-GPC3 T-cell engager SAR444200, in patients with advanced solid tumors.
2024 · Maxime Chenard-Poirier, Khaldoun Almhanna, et al. · Journal of Clinical Oncology
PDF
Corrigendum to “P-137: ITHACA, A Randomized Multicenter Phase 3 Study of Isatuximab in Combination With Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma: Safety Run-in Preliminary Results” [Clinical Lymphoma Myeloma and Leukemia 21 S2 (2021) S109- S110]
2022 · Irene M. Ghobrial, Paula Rodríguez-Otero, et al. · Clinical Lymphoma Myeloma & Leukemia
Works count: 11
Citation count: 307
H-index: 7
I10-index: 5
Year
Topic
Type